DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0312520 A1 Kennedy Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0312520 A1 Kennedy Et Al US 2011 0312520A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0312520 A1 Kennedy et al. (43) Pub. Date: Dec. 22, 2011 (54) METHODS AND COMPOSITIONS FOR Publication Classification DAGNOSING CONDITIONS (51) Int. Cl. (75) Inventors: Giulia C. Kennedy, San Francisco, CI2O I/68 (2006.01) CA (US); Darya I. Chudova, San C40B 30/04 (2006.01) Jose, CA (US); Jonathan I. Wilde, C40B 30/00 (2006.01) Burlingame, CA (US); James G. Veitch, Berkeley, CA (US); Bonnie H. Anderson, Half Moon Bay, CA (US) (52) U.S. Cl. ................ 506/9:435/6.14; 435/6. 12:506/7 (73) Assignee: Veracyte, Inc., South San Francisco, CA (US) (21) Appl. No.: 13/105,756 (57) ABSTRACT (22) Filed: May 11, 2011 The present invention relates to compositions, kits, and meth Related U.S. Application Data ods for molecular profiling for diagnosing disease conditions. .S. App In particular, the present invention provides molecular pro (60) Provisional application No. 61/333,717, filed on May files associated with thyroid cancer and other cancers, meth 11, 2010, provisional application No. 61/389,810, ods of relating molecular profiles to a diagnosis, and related filed on Oct. 5, 2010. compositions. Patent Application Publication Dec. 22, 2011 Sheet 1 of 28 US 2011/0312520 A1 FIGURE 1A Expression Analysis Gene Expression Level(s) Training/Reference Samples Biomarker Set/ Classifier 1 no match Training/Reference Samples Biomarker Set/ Classifier 2 Patent Application Publication Dec. 22, 2011 Sheet 2 of 28 US 2011/0312520 A1 &&&&#3:********** &&&&&&&&&&& Patent Application Publication Dec. 22, 2011 Sheet 3 of 28 US 2011/0312520 A1 FIGURE 1C 201 Module 1 (Module1.pm) Paralelized APT processes checksum apt-Cel-transformer e apt-probeset-Summarize (ps) apt-probeset-summarize (mps) apt-tSV-join Invocation interface Directory locking (LockDirpm) ConfigFile Handler (ConfigFile.pm), messages File Process Execution Patent Application Publication Dec. 22, 2011 Sheet 4 of 28 US 2011/0312520 A1 FIGURE 2 Gene Biomarker Panels for Diagnosing a Thyroid Condition Normal Thyroid (NML) Lymphocytic, Autoimmune Thyroiditis (LCT) Nodular Hyperplasia (NHP) Follicular Thyroid Adenoma (FA) Hurthle Cell Thyroid Adenoma (HA) Parathyroid (non thyroid tissue) (PTA) Anaplastic Thyroid Carcinoma (ATC) Follicular Thyroid Carcinoma (FC) Hurthle Cell Thyroid Carcinoma (HC) Papillary Thyroid Carcinoma (PTC) Follicular Variant of Papillary Carcinoma (FVPTC) Medullary Thyroid Carcinoma (MTC) Renal Carcinoma metastasis to the Thyroid (RCC) Melanoma metastasis to the Thyroid (MMN) B cell Lymphoma metastasis to the Thyroid (BCL) Breast Carcinoma metastasis to the Thyroid (BCA) Patent Application Publication Dec. 22, 2011 Sheet 5 of 28 US 2011/0312520 A1 FIGURE 3 Optimized Gene Classification Panels of Diagnostic Utility in Thyroid FNA Classification Subtype-specific Classifier Number of Markers Per Panel Panel Components MTC RCC PTA BCA MMN HA & HC 33 Benign/Suspicious 42 denotes the combination of two panels -HA and HC- into a single panel. denotes the combination of eight panels -FA, FC, NHP, PTC, FVPTC, LCT, HA, HC- into a single panel. Patent Application Publication Dec. 22, 2011 Sheet 6 of 28 US 2011/0312520 A1 FIGURE 4A TC) GENE Gene Description Classification Paned 336427 CALCA calcitonin-related polypeptide alpha MTC carcinoembryonic antigen-related cell adhesion 383434 CEACAMS molecule 5 MTC 35.94003 SCO3 secretogramin III - M - 2S854.00 SCN2A sodium channel, voltage-gated, type II, alpha subunit MTC sodium channel, voltage-gated, type IX, alpha 25854OO SCN9A subunit MTC 380S64 SYT4 synaptotagmin IV MTC 2923928 FABP7 fatty acid binding protein 7, brain RCC 3393446 FXYD2 FXYD domain containing ion transport regulator 2 RCC 288337 HAWCR hepatitis. A virus cellular receptor RCC 288337 LOCOOO1266 hepatitis. A virus cellular receptor pseudogene RCC 3428,225 NR14 nuclear receptor subfamily l, group II, member 4 RCC 2479698 PREPL prolyl endopeptidase-like RCC Solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic 2479698 SLC3A1 and neutral amino acid transport), member 1 RCC 3.1597.54 DMRT2 doublesex and mab-3 related transcription factor 2 PTA 2941690 GCM2 glial cells missing homolog 2 (Drosophila) PTA 33636.86 KDINS220 kinase D-interacting Substrate, 220kDa PTA 3484.895 KL klotho PTA 3363.686 PH parathyroid hormone PTA 2894790 SYCPL synaptonemal complex protein 2-like PTA 3O39830 AGR3 anterior gradient homolog 3 (Xenopus laevis) BCA 3264997 C10orfs chromosome 10 open reading frame 81 BCA V-myb myeloblastosis viral oncogene homolog 29268O2 MYB (avian) BCA 391.2079 SYCP2 synaptonema complex protein 2 BCA 243.63 WTCN1 V-set domain containing T cell activation inhibitor 1 BCA 3811949 CDII19 cadherin l9, type 2 MMN Patent Application Publication Dec. 22, 2011 Sheet 7 of 28 US 2011/0312520 A1 FIGURE 4B TCD GENE Gene Description Classification Panel 3.1626 MLANA melan-A MMN 39.354.86 SOOB S100 calcium binding protein B MMN 3457336 SLV silver homolog (mouse) MMN 33438.32 TYR tyrosinase (oculocutaneous albinism IA) MMN 3343832 TYRL tyrosinase-like (pseudogene) MMN HA & HC, 256.6848 AFF3 AF4/FMR2 family, member 3 Benign.Suspicious aminoacyl tRNA synthetase complex-interacting HA & HC. 2988882 AIMP2 multifunctional protein 2 Benign/Suspicious HA & HC, 316.933 ALDHB aldehyde dehydrogenasc 1 family, member Bl Bcnign.Suspicious HA & HC, 2.98466 BRP44L brain protein 44-like Benign/Suspicious HA & HC. 28224.92 C5orf30 chromosome 5 open reading frame 30 Benign/Suspicious HA & HC, 3326635 CD44 CD44 molecule (Indian blood group) Benign.Suspicious HA & HC, 2750627 CPE carboxypeptidase E Benign.Suspicious IIA & IIC, 3O4200 CYCS cytochrome c, Somatic Benign/Suspicious HA & HC, 3122678 DEFB1 defensin, beta 1 Benign.Suspicious HA & HC, 27393O8 EGF epidermal growth factor (beta-urogastrone) Benign.Suspicious eukaryotic translation initiation factor 2-alpha kinase HA & HC. 2988882 EIF2AK 1 Benign/Suspicious HA & HC, 36O3932 FAH fumarylacetoacetate hydrolase (fumarylacetoacetase) Benign.Suspicious HA & HC, 2970897 FRK fyn-related kinase Benign.Suspicious HA & HC. 3212008 FRMD3 FERM domain containing 3 Benign/Suspicious glutamic-oxaloacetic transaminasc 1, Soluble HA & HC, 33O2990 GOT (aspartate aminotransferase 1) Benign.Suspicious hydroxysteroid (17-beta) dehydrogenase 6 homolog HA & HC, 341 7703 ISD 736 (mouse) Benign/Suspicious HA & HC. 28775.08 HSPA9 heat shock 70kDa protein 9 (mortalin) Benign/Suspicious Patent Application Publication Dec. 22, 2011 Sheet 8 of 28 US 2011/0312520 A1 FIGURE 4C TC) GENE Gene Description Classification Panel HA & HC, 27O8922 GF2BP2 insulin-like growth factor 2 mRNA binding protein 2 Bcnign/Suspicious HA & HC, 2604998 IQCA IQ motif containing with AAA domain Benign.Suspicious integrin, beta 3 (platelet glycoprotein IIIa, antigen HA & HC, 3724.545 TGB3 CD61) Benign/Suspicious potassium inwardly-Tecifying channel, subfamily J, HA & HC, 3397.774 KCNJ member 1 Bcnign/Suspicious HA & HC, 2604998 LOCOO29258 hypothetical protein LOC10029258 Benign.Suspicious IIA & IIC, 3OO9299 MDI2 malate dehydrogenase 2, NAD (mitochondrial) Benign.Suspicious HA & HC, 3654699 NUPR1 nuclear protein, transcriptional regulator, 1. Benign/Suspicious HA & HC, 4O2O655 ODZ. odz, odd Oz ten-m homolog l(Drosophila) Benign/Suspicious HA & HC, 3970833 PDHA pyruvate dehydrogenase (lipoamide) alpha 1 Benign.Suspicious 6-phosphofructo-2-kinase/fructose-2,6- HA & HC, 237 7094 PFKFB2 biphosphatase 2 Benign/Suspicious HA & HC, 3278198 PHYH phytanoyl-CoA 2-hydroxylase Benign/Suspicious protein phosphatase 2 (formerly 2A), regulatory HA & HC, 288OO51 PPP2R2B Subunit B, beta isoform Benign.Suspicious HA & HC, 39598.62 PWALB parvalbumin Bcnign/Suspicious poliovirus receptor-related 2 (herpesvirus entry HA & HC, 2688499 PVRL2 mediator B) Benign.Suspicious IIA & IIC, 2604998 RPL3 ribosomal protein L3 Benign 'Suspicious HA & HC, 296423 RRAGD Ras-related GTP binding D Bcnign/Suspicious succinate dehydrogenase complex, subunit A, HA & HC, 2798.538 SDHA flavoprotein (Fp) Benign.Suspicious Succinate dehydrogenase complex, Subunit A, IIA & IIC, 2798.538 SDHALP flavoprotein pseudogene 1 Benign.Suspicious succinate dehydrogenase complex, subunit A, HA & HC, 2798.538 SDHALP2 flavoprotein pseudogene 2 Benign.Suspicious Patent Application Publication Dec. 22, 2011 Sheet 9 of 28 US 2011/0312520 A1 FIGURE 4D TCD GENE Gene Description Classificatio Pahel succinate dehydrogenase complex, subunit A. HA & HC, 2798.538 SDAP3 flavoprotein pseudogene 3 Benign/Suspicious solute carrier family l6, member 1 (monocarboxylic FIA & HC, 24285O1 SLC16A1 acid transporter 1) Benign/Suspicious IIA & C. 28775.08 SNORD63 - small nucleolar RNA C/D box 63 Benign/Suspicious HA & HC, 25.62529 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 Benign.Suspicious HA & HC, 2688499 ZBED2 zinc finger, BED-type containing 2 Benign.Suspicious ATP-binding cassettic, sub-family D (ALD), member 3450861 ABCD2 2. ------------------------------------------------------------ Benign Suspicious 334106 ACER3 alkaline ceramidase 3 Benign.Suspicious 27.96553 ACSL acyl-CoA synthetase long-chain family member 1 Benign.Suspicious 3375735 AHNAK AHNAK nucleoprotein Benign"Suspicious 2439554 AIM2 absent in melanoma 2 Benign.Suspicious 37684.74 ARSG arylsulfatase G Benign.Suspicious 32.14845 ASPN asporin Benign.Suspicious 3OO6572 AUTS2 autism susceptibility candidate 2 Benign.Suspicious 3902489 BCL2L1 BCL2-like 1 Benign/Suspicious 268877 | BTLA B and T lymphocyte associated Benign.Suspicious 2708855 C11orf72
Load more

Recommended publications
  • Radioisotope Imaging for Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules
    125 Review Article Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules Olivier Rager1,2, Piotr Radojewski1, Rebecca A. Dumont1, Giorgio Treglia3, Luca Giovanella3, Martin A. Walter1 1Nuclear Medicine Department, Geneva University Hospitals, Geneva, Switzerland; 2IMGE (Imagerie Moléculaire Genève), Geneva, Switzerland; 3Clinic of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Contributions: (I) Conception and design: O Rager, MA Walter; (II) Administrative support: MA Walter; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Olivier Rager, MD. Nuclear Medicine Department, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. Email: [email protected]. Abstract: The risk of malignancy in thyroid nodules with indeterminate cytological classification (Bethesda III–IV) ranges from 10% to 40%, and early delineation is essential as delays in diagnosis can be associated with increased mortality. Several radioisotope imaging techniques are available for discriminating benign from malignant cytologically indeterminate thyroid nodules, and for supporting clinical decision-making. These techniques include iodine-123, technetium-99m-pertechnetate, technetium-99m-methoxy-isobutyl- isonitrile (technetium-99m-MIBI), and fluorine-18-fluorodeoxyglucose (fluorine-18-FDG). This review discusses the currently available radioisotope imaging techniques for evaluation of thyroid nodules, including the mechanism of radiotracer uptake and the indications for their use. Keywords: Thyroid nodules; Bethesda III/IV; scintigraphy; positron emission tomography/computed tomography (PET/CT) Submitted Feb 11, 2019. Accepted for publication Mar 19, 2019.
    [Show full text]
  • Thyroid Nodules Are Extremely Common in the General Population
    2. THE PATHOLOGY OF THYROID CANCER SYLVIA L. ASA Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto; Pathologist-in-Chief, University Health Network and Toronto Medical Laboratories; Freeman Centre for Endocrine Oncology, Mount Sinai & Princess Margaret Hospitals; Toronto, Ontario Canada Thyroid nodules are extremely common in the general population; it has been esti- mated that about 20% of the population has a palpable thyroid nodule and approxi- mately 70% has a nodule that can be detected by ultrasound (1). The prevalence of thyroid nodules is greater in women than in men, and multiple nodules are more common than solitary nodules. The differential diagnosis of the thyroid nodule includes numerous entities, non-neoplastic and neoplastic, benign and malignant (2–5). The pathologist has an important role to play in their evaluation. The use of fine needle aspiration biopsy has significantly improved our ability to identify specific high-risk disorders and to facilitate their management in an expeditious and cost-effective manner. Patients who require surgery for further confirmation of the disease process rely upon the pathologist to correctly characterise their nodule and pathologists are actively involved in research to clarify the pathogenesis of thyroid disease. While some of these entities are readily diagnosed based on specific features seen in a routine slide stained with conventional dyes, the morphologic evaluation of many of these lesions is fraught with controversy and diagnostic criteria are highly variable from Pathologist to Pathologist (6). Nevertheless, histology remains the gold standard against which we measure outcomes of cytology, intraoperative consultations, molecular and other studies, and it represents the basis on which we determine patient management and the efficacy of various therapies.
    [Show full text]
  • Hürthle Cell Carcinoma)
    Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma) Qiong Yang1,*, Zhongsheng Zhao2,*, Guansheng Zhong1, Aixiang Jin1 and Kun Yu3 1 Department of Breast and Thyroid Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, P.R.China 2 Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, P.R.China 3 Department of Head, Neck & Thyroid Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, P.R.China * These authors contributed equally to this work. ABSTRACT Purpose. Radioactive iodine (RAI) is widely used for adjuvant therapy after thyroidec- tomy, while its value for thyroid cancer has been controversial recently. The primary objectives of this study were to clarify the influence of Radioactive iodine (RAI) on the survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma, HCC). Methods. Patients diagnosed with oxyphilic thyroid carcinoma from 2004 to 2015 were extracted from the Surveillance, Epidemiology, and End Results Program database. The Kaplan-Meier method was used to compare overall survival (OS) and cancer- specific survival (CSS) among patients who had adjuvant RAI use or not. Univariate and multivariate Cox proportional hazard models were performed for survival analysis, and subsequently visualized by nomogram. Results. In all, 2,799 patients were identified, of which 1529 patients had adjuvant RAI use while 1,270 patients had not. Based on multivariate Cox analysis, the RAI therapy Submitted 16 April 2019 confers an improved OS for HCC patients (HR D 0.57, 95% CI [0.44–0.72], P < 0:001), Accepted 10 July 2019 whereas it has no significant benefit in the survival analysis regarding CSS (HR D 0.79, Published 27 August 2019 95% CI [[0.47–1.34], P D 0:382).
    [Show full text]
  • My Approach to Oncocytic Tumours of the Thyroid S L Asa
    225 REVIEW J Clin Pathol: first published as 10.1136/jcp.2003.008474 on 27 February 2004. Downloaded from My approach to oncocytic tumours of the thyroid S L Asa ............................................................................................................................... J Clin Pathol 2004;57:225–232. doi: 11.1036/jcp.2003.008474 The traditional approach to oncocytic thyroid lesions staining. Morphologically, Hu¨rthle cells are characterised by large size, polygonal to square classified these as a separate entity, and applied criteria shape, distinct cell borders, voluminous granular that are somewhat similar to those used for follicular lesions and eosinophilic cytoplasm, and a large, often of the thyroid. In general, the guidelines to distinguish hyperchromatic nucleus with prominent ‘‘cherry pink’’ macronucleoli (fig 1). With the hyperplasia from neoplasia, and benign from malignant Papanicolau stain, the cytoplasm may be orange, were crude and unsubstantiated by scientific evidence. In green, or blue. By electron microscopy, the fact, there is no basis to separate oncocytic lesions from cytoplasmic granularity is produced by large mitochondria filling the cell, consistent with other classifications of thyroid pathology. The factors that oncocytic transformation.23 The diagnosis of an result in mitochondrial accumulation are largely unrelated oncocytic tumour is not usually difficult because to the genetic events that result in proliferation and of these distinctive features, but in borderline or dubious circumstances, mitochondrial markers neoplastic transformation of thyroid follicular epithelial can be used, including the antimitochondrial cells. The concept of classifying oncocytic lesions, including antibody 113-1. follicular variant papillary carcinomas, based on nuclear morphology, immunohistochemical profiles, and molecular ‘‘The proliferation of oncocytes gives rise to markers may pave the way for a better understanding of hyperplastic and neoplastic nodules’’ the biology of oncocytic lesions of the thyroid.
    [Show full text]
  • And Alters Mitochondrial Features in Follicular Thyroid Carcinoma Cells Through AKT/Gsk3β Pathway
    239 T B Mendes et al. Role of PVALB in the 23:9 769–782 Research pathogenesis of thyroid tumors PVALB diminishes [Ca2+] and alters mitochondrial features in follicular thyroid carcinoma cells through AKT/GSK3β pathway Thais Biude Mendes1, Bruno Heidi Nozima1, Alexandre Budu2, Rodrigo Barbosa de Souza1, Marcia Helena Braga Catroxo3, Rosana Delcelo4, Marcos Leoni Gazarini5 and Janete Maria Cerutti1 1Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, Brazil 2Enzymology Laboratory, Department of Biophysics, Universidade Federal de São Paulo, São Paulo, Brazil Correspondence 3Laboratory of Electron Microscopy, Center for Research and Development of Animal Health, Instituto Biológico, should be addressed S o Paulo, Brazil ã to J M Cerutti 4Department of Pathology, Universidade Federal de São Paulo, São Paulo, Brazil Email 5Cell Signaling Laboratory in Plasmodium, Department of Biosciences, Universidade Federal de São Paulo, Santos, [email protected] São Paulo, Brazil Abstract We have identified previously a panel of markers (C1orf24, ITM1 and PVALB) that can Key Words help to discriminate benign from malignant thyroid lesions. C1orf24 and ITM1 are f PVALB specifically helpful for detecting a wide range of thyroid carcinomas, and PVALB is f Hürthle cell adenoma Endocrine-Related Cancer Endocrine-Related particularly valuable for detecting the benign Hürthle cell adenoma. Although these f thyroid cancer markers may ultimately help patient care, the current understanding of their biological f AKT and GSKβ functions remains largely unknown. In this article, we investigated whether PVALB is critical for the acquisition of Hürthle cell features and explored the molecular mechanism underlying the phenotypic changes.
    [Show full text]
  • Thyroid Tumors with Follicular Architecture T ⁎ Andrew T
    Annals of Diagnostic Pathology 38 (2019) 51–58 Contents lists available at ScienceDirect Annals of Diagnostic Pathology journal homepage: www.elsevier.com/locate/anndiagpath Review Article Thyroid tumors with follicular architecture T ⁎ Andrew T. Turka, , Bruce M. Wenigb a Department of Pathology & Cell Biology, Columbia University, New York, NY, United States of America b Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, United States of America ABSTRACT Thyroid tumors with follicular architecture encompass a considerable array of distinct entities. These lesions share significant morphologic overlap, but portend different prognostic and therapeutic implications. Due to their similar growth patterns, distinction between these tumors can be difficult; remarkable interobserver variability exists, even between expert endocrine pathologists. Given the diagnostic challenges associated with these lesions, establishment of the correct diagnosis requires adequate gross examination protocol, careful attention to morphologic features and pathologic context, as well as—increasingly—adjunct molecular findings. In this review, we summarize the salient features of various follicular thyroid tumors, with special emphasis on the recently defined category of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), as well as the molecular pathology of these lesions. 1. Introduction 2. Follicular adenoma Follicular-patterned tumors of the thyroid represent a broad spec- Follicular adenoma (FA) is a benign neoplasm composed of folli- trum of lesions, with a wide variety of cytologic features, molecular cular epithelial cells. The tumor shows three hallmark histologic fea- alterations, and clinical implications. These lesions share considerable tures: follicular architecture; distinct patterning, relative to the unin- morphologic overlap in many instances, and proper diagnosis of folli- volved parenchyma; and encapsulation, or at least circumscription cular tumors can accordingly pose significant challenges.
    [Show full text]
  • Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid
    Pathology & Oncology Research (2019) 25:697–701 https://doi.org/10.1007/s12253-018-0546-x ORIGINAL ARTICLE Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid Li Ding1 & Yunhui Jiang2 & Wan Yang1 Received: 12 August 2018 /Accepted: 16 November 2018 /Published online: 11 December 2018 # Arányi Lajos Foundation 2018 Abstract To observe the expression of P53, CyclinD1, Ki-67, Galectin-3, COX-2, Bcl-2 and approach their contribution on assessing the invasive potential for Hurthle cell tumors. Seventy-three cases of Hurthle cell tumor were collected for immunohistochemistry staining. The patients were followed up with 8 months to 5 years. Tumors were divided into four grades according to invasion and diameter:(1) extremely low risk (27 cases that less than 2 cm and without invasion), (2) low risk (18 cases that within 2–3.9 cm and without invasion), (3) moderate risk (21 cases that achieve 4 cm and without invasion), (4) high risk (7 cases that with invasion of capsule/vessel in spite of the diameter). Immunostaining presented that all 73 cases were positive with Galectin-3, COX-2 and Bcl-2. For each group, P53 positive were 29.6%, 55.6%, 90.5%, 100.0%; CyclinD1 stained with 7.4%,22.2%,52.4%,100.0% and Ki-67 were 0.0%,5.6%,9.5%,28.6%, respectively. The higher risk of tumor, the more cases that positive expressed P53 and CyclinD1. After following up within 49 patients, two of the recurring cases were positive with P53 and CyclinD1 and one of which was also highly expressed Ki-67.
    [Show full text]
  • Hurthle Cell Tumours of the Thyroid. Personal Experience and Review of the Literature Il Carcinoma a Cellule Di Hurthle Della Tiroide
    ACTA OTORHINOLARYNGOLOGICA ITALICA 2009;29:305-311 Hurthle cell tumours of the thyroid. Personal experience and review of the literature Il carcinoma a cellule di Hurthle della tiroide. Nostra casistica e revisione della letteratura A. BARNABEI, E. FERRETTI, R. BALDELLI, A. PROCACCINI1, G. SPRIANO2, M. APPETECCHIA Endocrinology Unit, Regina Elena National Cancer Institute, Rome; 1 Otorhinolaryngology Unit, S. Camillo de Lellis Hospital, Rieti; 2 Department of Otorhinolaryngology Head and Neck Surgery, Regina Elena National Cancer Institute, Rome, Italy SUMMARY Hurthle cell carcinoma represents about 5% of differentiated thyroid carcinomas. The prognosis of the malignant type of the tumour is still under debate as some Authors have reported that Hurthle cell adenoma occasionally behaves like Hurthle cell carcinoma. Aim of the present study was to evaluate previously reported data and personal experience on the clinical and pathological features of patients affected by Hurthle cell tumour that may predict disease progression and death. In the literature, factors potentially associated with decreased survival were identifi ed and include: age, disease stage, tumour size, extra-glandular invasion, lymph node disease, distant metastases, extensive surgery, radioiodine treatment. From 1992 to 2003, the Authors identifi ed 28 patients affected by Hurthle cell tumour, 9 with Hurthle cell adenoma and 19 with Hurthle cell carcinoma. Of these, 22 were females and 6 males. Mean age of patients affected by adenoma was 49.7 years (range 30-72) vs. 49.3 years (range 15-72) in Hurthle cell carcinoma patients. In all patients, total thyroidectomy was performed. At histology, 9 adenomas, 5 “minimally invasive” and 14 invasive carcinomas were found.
    [Show full text]
  • Thyroid Hürthle Cell Carcinoma: Clinical, Pathological, and Molecular Features
    cancers Review Thyroid Hürthle Cell Carcinoma: Clinical, Pathological, and Molecular Features Shoko Kure * and Ryuji Ohashi Integrated Diagnostic Pathology, Nippon Medical School, 1-1-5 Sendagi, Bunkyoku, Tokyo 113-8602, Japan; [email protected] * Correspondence: [email protected] Simple Summary: Hürthle cell carcinoma (HCC) represents 3–4% of thyroid carcinoma cases. It is characterized by its large, granular and eosinophilic cytoplasm, due to an excessive number of mitochondria. Hürthle cells can be identified only after fine needle aspiration cytology biopsy or by histological diagnosis after the surgical operation. Published studies on HCC indicate its putative high aggressiveness. In this article, current knowledge of HCC focusing on clinical features, cytopathological features, genetic changes, as well as pitfalls in diagnosis are reviewed in order to improve clinical management. Abstract: Hürthle cell carcinoma (HCC) represents 3–4% of thyroid carcinoma cases. It is considered to be more aggressive than non-oncocytic thyroid carcinomas. However, due to its rarity, the pathological characteristics and biological behavior of HCC remain to be elucidated. The Hürthle cell is characterized cytologically as a large cell with abundant eosinophilic, granular cytoplasm, and a large hyperchromatic nucleus with a prominent nucleolus. Cytoplasmic granularity is due to the presence of numerous mitochondria. These mitochondria display packed stacking cristae and are arranged in the center. HCC is more often observed in females in their 50–60s. Preoperative diagnosis is challenging, but indicators of malignancy are male, older age, tumor size > 4 cm, a solid nodule with an irregular border, or the presence of psammoma calcifications according to ultrasound. Thyroid lobectomy alone is sufficient treatment for small, unifocal, intrathyroidal carcinomas, or Citation: Kure, S.; Ohashi, R.
    [Show full text]
  • Hurthle Cell Adenoma and Papillary Microcarcinoma in Thyroid: Collision Tumors 1Chanchal Rana, 2Niraj Kumari
    WJOES Chanchal Rana, Niraj Kumari 10.5005/jp-journals-10002-1232 CASE REPORT Hurthle Cell Adenoma and Papillary Microcarcinoma in Thyroid: Collision Tumors 1Chanchal Rana, 2Niraj Kumari ABSTRACT CASE REPORT The combination of more than one thyroid carcinoma variants A 45-year-old lady presented with anterior neck swelling has been reported very rarely which includes combination of for 3 years duration which was progressively increasing follicular carcinoma with papillary carcinoma, medullary car- cinoma with follicular carcinoma and anaplastic, and follicular in size. There was no history of rapid increase in size, and papillary carcinoma with follicular adenoma. We report pain over swelling, or any compressive symptoms like another combination of Hurthle cell adenoma with incidental change of voice or dysphagia. occurrence of micropapillary carcinoma adding to the group of On examination, there was a well-defined 8 × 7 cm collision tumors in thyroid. firm swelling that moved with deglutition in right lobe Keywords: Collision tumor, Hurthle cell adenoma, Papillary of thyroid. There were no palpable regional lymph nodes, microcarcinoma. carotid bruit, or retrosternal extension. Trachea was devi- How to cite this article: Rana C, Kumari N. Hurthle Cell ated toward left. Rest of the systemic examination was Adenoma and Papillary Microcarcinoma in Thyroid: Collision largely unremarkable. Tumors. World J Endoc Surg 2018;10(2):134-136. Biochemical investigations showed triiodothyronine Source of support: Nil of 1.86 nmol/L (normal range 1.3–2.8 nmol/L), thyrox- Conflict of interest: None ine of 88.7 nmol/L (normal range 60–180 nmol/L), and thyroid-stimulating hormone of 2.76 mIU/L (normal INTRODUCTION range 0.3–5 mIU/L).
    [Show full text]
  • Management of Thyroid Nodules
    B-ENT, 2007, 3, Suppl. 6, 93-102 Management of thyroid nodules J. P. Monnoye*, M. Hamoir**, C. de Burbure***, G. Chantrain****, P. Gasmanne*****, P. Levie*, R. Loncke******, O. Desgain*, V. Monnoye* and Ch. Malherbe******* *Department of Otolaryngology, Cliniques Ste Anne-St Remi, Brussels; **Department of Otolaryngology, Head and Neck Surgery, St Luc University Hospital, Catholic University of Louvain, Brussels; ***Pathology, St-Luc University Hospital, Catholic University of Louvain, Brussels; ****Department of Otolaryngology, University Hospital St-Pierre, ULB, Brussels; *****Department of Otolaryngology, CHU Charleroi, Charleroi; ******Department of Otolaryngology, H. Hartziekenhuis, Roeselare; *******Internal Medicine Department, Endocrine-Metabolic Unit, Brussels Key-words. Guidelines; thyroid nodules; review; management Abstract. Management of thyroid nodules. These Belgian guidelines for ENT surgeons about thyroid nodules were elaborated in the light of personal practical experience and the recent advances in diagnosis and management described in the literature. Thyroid nodules are a common finding, particularly in women and in areas of iodine depletion. The prevalence in the general population averages 3 to 7% on palpation and almost 50% on ultrasound. The major difficulty facing the clinician is how best to assess and manage these thyroid nodules. The authors have attempted to simplify the assessment of thyroid nodules, to classify them, and to present the most common current therapeutic management options. 1. Introduction in men and the prevalence 2. Benign nodules increases in areas with iodine The following guidelines are deficiency and ionizing radiation 2.1. Adenomas based on recent peer-reviewed exposure.10 2.1.1. Follicular adenoma is a articles evaluated by the authors to On ultrasonography the preva- common thyroid tumour, with a rate between Ia and III according lence ranges from 19% to 46% in greater incidence in women than to Belgian evidence levels the general population, may be in men.
    [Show full text]
  • Significance of Hurthle Cells in Thyroid Cytology
    SIGNIFICANCE OF HURTHLE CELLS IN THYROID CYTOLOGY A dissertation submitted to The Tamil Nadu Dr.M.G.R. Medical University, Chennai in partial fulfillment for the award of M.D. Degree in PATHOLOGY (BRANCH III) INSTITUTE OF PATHOLOGY AND ELECTRON MICROSCOPY MADRAS MEDICAL COLLEGE AND RESEARCH INSTITUTE THE T.N. Dr.M.G.R. MEDICAL UNIVERSITY CHENNAI - 600 003. CERTIFICATE This is to certify that this dissertation entitled "SIGNIFICANCE OF HURTHLE CELLS IN THYROID CYTOLOGY" is a bonafide work done by Dr.V.ESWARI, in partial fulfillment of regulations of the TAMIL NADU Dr.M.G.R. MEDICAL UNIVERSITY, Chennai. DIRECTOR GUIDE Prof.Dr.A.V.SHANTI, M.D., Prof.Dr.SHANTA RAVISANKAR, MD.D.C.P., Director and Head, Professor of Neuro Pathology, Institute of Pathology & Institute of Pathology & Electron Microscopy, Electron Microscopy, Madras Medical College, Madras Medical College, Chennai - 600 003 Chennai - 600 003 DEAN Prof.Dr.KALAVATHI PONNIRAIVAN, B.Sc., M.D., Dean Madras Medical College & Government General Hospital, Chennai - 600 003 DECLARATION I declare that this dissertation entitled "SIGNIFICANCE OF HURTHLE CELLS IN THYROID CYTOLOGY" has been conducted by me under the guidance and supervision of Prof. Dr.Shanta Ravisankar, M.D.,D.C.P., in the Institute of Pathology and Electron Microscopy, Madras Medical College. It is submitted in partial fulfillment of the requirements for the award of the M.D. Pathology, September 2006 examination to be held under Dr.M.G.R.Medical University, Chennai. This has not been submitted by me for the award of any degree or diploma from any other University.
    [Show full text]